U.S. markets close in 3 hours 45 minutes
  • S&P 500

    4,178.06
    +10.47 (+0.25%)
     
  • Dow 30

    34,384.43
    +154.09 (+0.45%)
     
  • Nasdaq

    13,564.92
    -17.50 (-0.13%)
     
  • Russell 2000

    2,226.00
    -15.36 (-0.69%)
     
  • Crude Oil

    65.12
    -0.51 (-0.78%)
     
  • Gold

    1,815.30
    +31.00 (+1.74%)
     
  • Silver

    27.50
    +0.98 (+3.71%)
     
  • EUR/USD

    1.2055
    +0.0046 (+0.39%)
     
  • 10-Yr Bond

    1.5710
    -0.0130 (-0.82%)
     
  • GBP/USD

    1.3888
    -0.0020 (-0.14%)
     
  • USD/JPY

    109.1190
    -0.0700 (-0.06%)
     
  • BTC-USD

    57,148.00
    -552.27 (-0.96%)
     
  • CMC Crypto 200

    1,485.74
    +14.33 (+0.97%)
     
  • FTSE 100

    7,076.17
    +36.87 (+0.52%)
     
  • Nikkei 225

    29,331.37
    +518.77 (+1.80%)
     

No­vo Nordisk To Start Phase 3 Obe­si­ty Tri­al With Oral Semaglu­tide

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Novo Nordisk A/S (NYSE: NVO) is entering the Phase 3a study in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a trial with once-weekly subcutaneously administered semaglutide 2.4 mg.

  • The company will launch the trial in the second half of 2021, planning to measure a 50 mg semaglutide pill compared to a placebo. The study will recruit about 1,000 patients and last for 68 weeks.

  • “With oral semaglutide, we aim to introduce a convenient and effective treatment option for people with obesity and healthcare providers enabling broader use of anti-obesity medication,” said R&D chief Martin Holst Lange in a statement.

  • Previously, Novo had reported success for semaglutide to treat obesity, which entailed receiving 2.4 mg of the drug through subcutaneous injection once a week. In nearly a 2,000-person trial, patients in the drug arm saw an average of 15% weight loss, compared with just 2.4% on placebo.

  • Price Action: NVO shares are up 1.02% at $74.03 in market hours on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.